We did not include, however, groups at intermediate stages of the Alzheimer’s disease continuum, e.g. participants with evidence of significant Aβ but not tau accumulation that should be studied in future works. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.